181 related articles for article (PubMed ID: 32351149)
1. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.
Ahern TP; Damkier P; Feddersen S; Kjærsgaard A; Lash TL; Hamilton-Dutoit S; Lythjohan CB; Ejlertsen B; Christiansen PM; Cronin-Fenton DP
Acta Oncol; 2020 Sep; 59(9):1009-1015. PubMed ID: 32351149
[No Abstract] [Full Text] [Related]
2. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.
Ahern TP; Pedersen L; Tarp M; Cronin-Fenton DP; Garne JP; Silliman RA; Sørensen HT; Lash TL
J Natl Cancer Inst; 2011 Oct; 103(19):1461-8. PubMed ID: 21813413
[TBL] [Abstract][Full Text] [Related]
3. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
5. Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients.
Ahern TP; Collin LJ; Baurley JW; Kjærsgaard A; Nash R; Maliniak ML; Damkier P; Zwick ME; Isett RB; Christiansen PM; Ejlertsen B; Lauridsen KL; Christensen KB; Silliman RA; Sørensen HT; Tramm T; Hamilton-Dutoit S; Lash TL; Cronin-Fenton D
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):582-590. PubMed ID: 31932415
[TBL] [Abstract][Full Text] [Related]
6. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
7. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
8. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
9. Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Bailey KM; Romaine SP; Jackson BM; Farrin AJ; Efthymiou M; Barth JH; Copeland J; McCormack T; Whitehead A; Flather MD; Samani NJ; Nixon J; Hall AS; Balmforth AJ;
Circ Cardiovasc Genet; 2010 Jun; 3(3):276-85. PubMed ID: 20207952
[TBL] [Abstract][Full Text] [Related]
10. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
[TBL] [Abstract][Full Text] [Related]
11. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
12. Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Rørth M; Ejlertsen B; Lash TL; Ahern TP; Sørensen HT; Cronin-Fenton D
Breast Cancer Res Treat; 2022 Jul; 194(2):353-363. PubMed ID: 35501422
[TBL] [Abstract][Full Text] [Related]
13. Genomewide Association Study of Simvastatin Pharmacokinetics.
Mykkänen AJH; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Tarkiainen EK; Lilius T; Tapaninen T; Backman JT; Tornio A; Niemi M
Clin Pharmacol Ther; 2022 Sep; 112(3):676-686. PubMed ID: 35652242
[TBL] [Abstract][Full Text] [Related]
14. Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin.
Kitzmiller JP; Luzum JA; Dauki A; Krauss RM; Medina MW
Clin Transl Sci; 2017 May; 10(3):172-177. PubMed ID: 28482130
[TBL] [Abstract][Full Text] [Related]
15. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
16. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
[TBL] [Abstract][Full Text] [Related]
17. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.
Ahangari N; Doosti M; Ghayour Mobarhan M; Sahebkar A; Ferns GA; Pasdar A
Ann Med; 2020 Dec; 52(8):462-470. PubMed ID: 32735150
[TBL] [Abstract][Full Text] [Related]
18. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
[TBL] [Abstract][Full Text] [Related]
20. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
